Hemophilia

HCV-positive hemophiliacs get comprehensive cancer therapy with surveillance

Published in Hepatitis Weekly, July 7th, 2003

by Sonia Nichols, senior medical writer - Hemophiliacs who undergo regular surveillance for hepatocellular carcinoma, or primary liver cancer, tend to receive therapy that may ultimately reduce mortality risk.

"Hepatocellular carcinoma (HCC)is an increasingly frequent cause of mortality in hemophiliacs with chronic viral hepatitis. Early diagnosis of the tumor at an initial stage is known to improve the outcome of HCC treatment," Elena Santagostino and colleagues wrote in the journal Blood. Santagostino is a researcher at the IRCCS Maggiore Hospital in Milan Italy, and her team is affiliated with the Study Group of the Association of Italian Hemophilia Centers,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-07-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry